Fondazione Neoplasie Sangue Onlus   Report issue

Foundation Phase 2 Phase 3
Founded: Torino Italy (2004)

Organization Overview

First Clinical Trial
2006
NCT01063179
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Fondazione Neoplasie Sangue Onlus

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease Progression (Phase 2)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Recurrence (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 12